Public Release:  Targeting disease remission has socio-economic benefits over low disease activity

Achieving remission in more patients could lessen the burden of rheumatoid arthritis on societies with aging populations

European League Against Rheumatism

Rome, Italy, Saturday 19 June 2010: Achieving disease remission in patients with rheumatoid arthritis (RA) provides superior outcomes across measures of socio-economic importance including work productivity and quality of life according to results presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. These Austrian findings are reported in addition to improvements in measures of physical functioning, when compared with RA patients achieving low disease activity (LDA).

Results from this cross-sectional study of 356 patients showed statistically significant differences (p= < 0.01) between RA patients who had achieved disease remission (REM, defined by the Clinical disease activity Index (CDAI), a composite index including objective and patient derived scores) compared to those who had achieved LDA across several domains including:

  • Effect on work productivity, based on results of the Work Productivity and Activity Impairment (WPAI*) index: impairment while working 11.3% vs. 27.2%, overall activity impairment 18.1% vs. 33.8%, REM vs LDA respectively
  • Impact on quality of life, based on results of the Euro Qol (5D EQ-5D)* index: 0.89 vs. 0.78 and the SF-36 PCS* index: 46.2 vs. 37.8
  • Impact on physical functioning, based on results of the Health Assessment Questionnaire (HAQ*) scores: 0.38 vs. 0.75.

"We know that RA as a chronic disease often has a long term impact on patients' functional ability, affecting not only patients' well-being but also their working lives. The majority of those affected report a loss of productivity at work, and many even have to stop work altogether," said Dr. Helga Radner, Department of Rheumatology, Medical University Vienna, Austria and lead author of the study. "Our study results show that the benefits of achieving clinical remission are worthwhile, especially from a socio-economic point of view, as it decreases the 'burden of disease' not only for patients but also for society on a wider scale. The findings reveal that remission is even superior to an almost perfect disease activity state, namely low disease activity, therefore our major task in treating RA-patients should be its achievement and maintenance"

Interestingly, researchers found that the emotional aspects of the disease activity measures were similarly reported in patients in remission and in low disease activity indicating that once disease activity or symptom levels are reduced to a certain level, emotional discord may stabilise.

Longitudinal analysis over one year showed significant improvements when comparing the two patient populations in the following areas:

  • Quality of life (EQ-5D); 0.89 vs. 0.80 (REM vs. LDA respectively), p < 0.001
  • Percent of overall activity impairment (WPAI) per year; 12.2% vs. 31.0%, p < 0.001
  • Physical disability (HAQ); 0.23 vs. 0.69, p= < 0.001

Significant differences between REM and LDA were not seen in the domain of percentage impairment while working (8.3% vs. 20.0% (REM vs. LDA respectively), p=0.096).

This study of 356 patients registered at the Department of Rheumatology at the Medical University of Vienna involved one cross sectional analysis (at a single time point) of RA patients, with 34 patients achieving REM (CDAI ≤2.8) and 66 patients achieving LDA (2.8≤CDAI<1).

* HAQ is a disability index used by physicians to measure an individual's physical functioning and assesses ability to undertake everyday activities such as dressing, eating and walking, and whether assistance from another person or disability aids is required. A higher score indicates greater disability.

The WPAI questionnaire measures work time missed and work and activity impairment due to a specified health problem during the last 7 days.

The (EQ-5D) is a health-related quality of life scale consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) to which responses can be made at three levels of severity (no problems/some or moderate problems/extreme problems).

The Short Form 36 (SF36) SF-36 is a multi-purpose health survey which yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures.

The Clinical Disease Activity Index allows the assessment of actual disease activity, response to therapy, and achievement of particular states such as remission. The simplicity of the scoring system facilitates patient understanding of the level of their disease activity.

###

Abstract Number: SAT0026

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office on the 1st floor in Hall 5 of the Congress Centre during EULAR 2010 or on:
Email: eularpressoffice@uk.cohnwolfe.com
Rory Berrie: Onsite tel: +44 7901 513 297
Caroline Butt: Onsite tel: +44 7789 270 392

About EULAR

  • The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations.
  • In line with The European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.
  • The aims of EULAR are to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with rheumatic diseases.
  • EULAR 2010 is set to be the biggest rheumatology event in Europe with over 15,000 scientists, physicians, allied health professionals, and related audiences in attendance from over 100 countries. Over the course of the congress, almost 300 oral and more than 1600 poster abstract presentations will be featured, with 300 invited speaker lectures taking place in more than 140 sessions.
  • To find out more about the activities of EULAR, visit: www.eular.org

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.